GeneDx Holdings Executive Compensation (FY25)
WGS · Executive and director compensation, fiscal 2024 to 2025
The paid brief on GeneDx Holdings
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Data as of September 7, 2026Latest filing (8-K): June 23, 2026
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
128 figures on this page: 127 cited to the filing that reported them, 1 calculated from figures it prints. See the citations
More on GeneDx Holdings
Five data products on this company. Each one is requested through the developer setup page.
- Peer Disclosure Audit$5The comparison companies this board named, each one tied to the filing that lists it.How to get Peer Disclosure Audit
- Governance Provisions PullfreeThe governance provisions as the proxy states them: board leadership, committee membership, and shareholder rights.How to get Governance Provisions Pull
- Say-on-Pay Risk Signal$9A risk band for the next say-on-pay vote, with the support history and the peer comparison behind it.How to get Say-on-Pay Risk Signal
- NEO Comp Report$24Every named executive officer’s pay by element and year, with the citation behind each figure.How to get NEO Comp Report
- Board Comp Report$24What each non-employee director was paid, the standing fee schedule, and the equity each one holds at year end.How to get Board Comp Report
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Katherine Stueland: $4,421,800 → $13,547,219 (206.4% higher)
Frequently asked questions
Answers drawn from the data on this page.
Who is GeneDx Holdings' chief executive and what were they paid?
Total compensation for Katherine Stueland, Chief Executive Officer, came to $13,547,219 in fiscal 2025. Compared with the $4,421,800 reported for fiscal 2024, Stueland's total was 206.4% higher.
What was GeneDx Holdings' say-on-pay result?
The say-on-pay proposal drew 93.9% of votes cast for or against in favor at the meeting held June 18, 2026 for fiscal 2025.
Which companies are in GeneDx Holdings' peer group?
The disclosed peer group names 10x Genomics, Axogen, CareDx, Castle Biosciences and Cerus, among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Katherine Stueland Chief Executive Officer | ◇ | ◇ | ◇ | — | — | — | — | ◇ |
Kevin Feeley Chief Financial Officer | ◇ | ◇ | ◇ | — | — | — | ◇ | ◇ |
Jason Ryan Former Executive Chairman of the Board and Chairman of the Board Departed during or after this year | ◇ | — | ◇ | — | — | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Katherine Stueland Chief Executive Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Kevin Feeley Chief Financial Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Bryan Dechairo Chief Operating Officer | ◇ | ◇ | ◇ | — | ◇ | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Bryan Dechairo | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Katherine Stueland | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Katherine Stueland | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Kevin Feeley | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Kevin Feeley | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
Fiscal 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Katherine Stueland | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 5/2/2032 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Kevin Feeley | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 9/1/2032 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 5/2/2032 | |
| RSU | ◇ | ◇ | — | — | |
| Bryan Dechairo | RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Severance and change in control
The terms as written in the agreements.
Bryan Dechairo
Chief Operating Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance multiple | ◇ |
| Severance base | ◇ |
| Severance cash amount | ◇ |
| Change-in-control multiple | ◇ |
Katherine Stueland
Chief Executive Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance multiple | ◇ |
| Severance base | ◇ |
| Severance cash amount | ◇ |
| Change-in-control multiple | ◇ |
Kevin Feeley
Chief Financial Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance multiple | ◇ |
| Severance base | ◇ |
| Severance cash amount | ◇ |
| Change-in-control multiple | ◇ |
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Thomas Fuchs | ◇ | ◇ | — | — | — | — | ◇ |
Jason Ryan Board chair | ◇ | ◇ | — | — | — | ◇ | ◇ |
Emily Leproust | ◇ | ◇ | — | — | — | — | ◇ |
Joshua Ruch | ◇ | ◇ | — | — | — | — | ◇ |
Keith Meister | ◇ | ◇ | — | — | — | — | ◇ |
Eli D. Casdin | ◇ | ◇ | — | — | — | — | ◇ |
Richard C. Pfenniger, Jr | ◇ | ◇ | — | — | — | — | ◇ |
Katherine Stueland served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as restricted stock units.
Stock ownership guideline: 300% of annual cash director retainer
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- 10x Genomics TXG
- Axogen AXGN
- CareDx CDNA
- Castle Biosciences CSTL
- Cerus CERS
- Mirum Pharmaceuticals MIRM
- Natera NTRA
- NeoGenomics NEO
- Pacific Biosciences of California PACB
- Standard BioTools LAB
- Veracyte VCYT
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 18, 2026 | = | ◇ | ◇ | ◇ |
What this page does not include
Everything above is a fact GeneDx Holdings disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where GeneDx Holdings sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
128 figures on this page: 127 cited to the filing that reported them, 1 calculated from figures it prints.
127 cited to the filing
1 calculated from the filing
Documents cited
- 0001628280-26-044806
- 0001818331-26-0000302025 Director Compensation Table · 2025 SUMMARY COMPENSATION TABLE · Compensation Discussion and Analysis · Director Compensation · and 2 more sections
- 0001818331-25-0000752024 Summary Compensation Table
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “GeneDx Holdings executive compensation, FY2024–FY2025.” https://intel.velarion.ai/comp/WGS (accessed 2026).
Short form: data: Velarion
The paid brief for GeneDx Holdings
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about GeneDx Holdings and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers GeneDx Holdings discloses
The companies named in WGS's own disclosed peer group.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}